Loss of chromatic sensitivity in AMD and diabetes: a comparative study

O'neill‐Biba, M; Sivaprasad, Sobha; Rodriguez‐Carmona, Marisa; Wolf, Janet E.; Barbur, John L.

doi:10.1111/j.1475-1313.2010.00775.x

Cited by 54 publications

(53 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although several studies have shown that color vision deteriorates with advancing age [23,24], some controversy remains as to whether normal aging affects more the YB mechanism [25]. Diseases of the eye, such as diabetes, tend to affect uniformly both RG and YB mechanisms, although the loss of YB sensitivity precedes RG in early stage age-related macular degeneration [26]. The prevalence of retinal and systemic diseases that affect vision increases with age and almost invariably these cause loss of chromatic sensitivity.…”

Section: Introductionmentioning

confidence: 99%

Changes in color vision with decreasing light level: separating the effects of normal aging from disease

Barbur¹,

Konstantakopoulou²

2012

J. Opt. Soc. Am. A

View full text Add to dashboard Cite

This is the unspecified version of the paper.This version of the publication may differ from the final published version. The purpose of this study was to obtain additional information about the health of the retina (HR) by measuring the rate of loss of chromatic sensitivity with decreasing light level. The HR index is introduced to separate the effects of normal aging from early stage disease. For normal subjects the HR index is largely independent of age (r 2 ∼ 0.1), but ∼11% of clinically normal, asymptomatic, older subjects exhibit values below the 2σ limit. The HR index provides a single number that captures how light level affects chromatic sensitivity irrespective of age and can be used to screen for preclinical signs of retinal disease. Permanent

show abstract

Section: Introductionmentioning

confidence: 99%

Changes in color vision with decreasing light level: separating the effects of normal aging from disease

Barbur¹,

Konstantakopoulou²

2012

J. Opt. Soc. Am. A

View full text Add to dashboard Cite

show abstract

“…Color vision deficiencies may be congenital or secondary to disease and often manifest as a decreased ability to differentiate between shades of a color or between two or more colors. Ocular conditions such as diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucoma are known to affect color vision prior to affecting visual acuity (VA) (Greenstein, Hood, Ritch, Steinberger, & Carr, 1989;O'Neill-Biba, Sivaprasad, Rodriguez-Carmona, Wolf, & Barbur, 2010). In individuals with diabetes mellitus (DM), color vision impairment has been documented to emerge in the early stages of the disease and may precede the development of DR (Feitosa-Santana et al, 2006;Kurtenbach, Schiefer, Neu, & Zrenner, 1999;.…”

Section: Introductionmentioning

confidence: 99%

Normative values for a tablet computer-based application to assess chromatic contrast sensitivity

et al. 2017

View full text Add to dashboard Cite

Tablet computer displays are amenable for the development of vision tests in a portable form. Assessing color vision using an easily accessible and portable test may help in the self-monitoring of vision-related changes in ocular/ systemic conditions and assist in the early detection of disease processes. Tablet computer-based games were developed with different levels of gamification as a more portable option to assess chromatic contrast sensitivity. Game 1 was designed as a clinical version with no gaming elements. Game 2 was a gamified version of game 1 (added fun elements: feedback, scores, and sounds) and game 3 was a complete game with vision task nested within. The current study aimed to determine the normative values and evaluate repeatability of the tablet computer-based games in comparison with an established test, the Cambridge Colour Test (CCT) Trivector test. Normally sighted individuals [N = 100, median (range) age 19.0 years (18-56 years)] had their chromatic contrast sensitivity evaluated binocularly using the three games and the CCT. Games 1 and 2 and the CCT showed similar absolute thresholds and tolerance intervals, and game 3 had significantly lower values than games 1, 2, and the CCT, due to visual task differences. With the exception of game 3 for blue-yellow, the CCT and tablet computer-based games showed similar repeatability with comparable 95% limits of agreement. The custom-designed games are portable, rapid, and may find application in routine clinical practice, especially for testing younger populations.

show abstract

“…Chromatic thresholds will be measured for the eye with early AMD using the Colour Assessment and Diagnosis test [48] (City Occupational Ltd). Contrast thresholds to a 14 Hz flickering stimulus will be measured for the eye with early AMD using the procedure outlined by Dimitrov et al [49].…”

Section: Methodsmentioning

confidence: 99%

Low-level night-time light therapy for age-related macular degeneration (ALight): study protocol for a randomized controlled trial

McKeague

Margrain

Bailey

et al. 2014

Trials

View full text Add to dashboard Cite

BackgroundAge-related macular degeneration (AMD) is the leading cause of blindness among older adults in the developed world. The only treatments currently available, such as ranibizumab injections, are for neovascular AMD, which accounts for only 10 to 15% of people with the condition. Hypoxia has been implicated as one of the primary causes of AMD, and is most acute at night when the retina is most metabolically active. By increasing light levels at night, the metabolic requirements of the retina and hence the hypoxia will be considerably reduced. This trial seeks to determine whether wearing a light mask that emits a dim, green light during the night can prevent the progression of early AMD.Methods/designALight is a Phase I/IIa, multicentre, randomized controlled trial. Sixty participants (55 to 88 years old) with early AMD in one eye and neovascular AMD (nAMD) in the fellow eye will be recruited from nAMD clinics. They will be randomized (in the ratio 1:1), either to receive the intervention or to be in the untreated control group, stratified according to risk of disease progression. An additional 40 participants with healthy retinal appearance, or early AMD only, will be recruited for a baseline cross-sectional analysis. The intervention is an eye mask that emits a dim green light to illuminate the retina through closed eyelids at night. This is designed to reduce the metabolic activity of the retina, thereby reducing the potential risk of hypoxia. Participants will wear the mask every night for 12 months. Ophthalmologists carrying out monthly assessments will be masked to the treatment group, but participants will be aware of their treatment group. The primary outcome measure is the proportion of people who show disease progression during the trial period in the eye with early AMD. A co-primary outcome measure is the rate of retinal adaptation. As this is a trial of a CE-marked device for an off-label indication, a further main aim of this trial is to assess safety of the mask in the cohort of participants with AMD.Trial registrationInternational Standard Randomised Controlled Trials Register: ISRCTN82148651

show abstract

Loss of chromatic sensitivity in AMD and diabetes: a comparative study

Abstract: These findings suggest that accurate measurements of RG and YB colour thresholds can provide a sensitive measure of functional change in diseases of the retina with patterns of loss that differ significantly in AMD and diabetes.

Cited by 54 publications

References 49 publications

Changes in color vision with decreasing light level: separating the effects of normal aging from disease

Changes in color vision with decreasing light level: separating the effects of normal aging from disease

Normative values for a tablet computer-based application to assess chromatic contrast sensitivity

Low-level night-time light therapy for age-related macular degeneration (ALight): study protocol for a randomized controlled trial

Contact Info

Product

Resources

About